Pfizer Inc. (NYSE:PFE) Shares Sold by Altus Wealth Group LLC

Altus Wealth Group LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.9% in the second quarter, HoldingsChannel reports. The firm owned 9,233 shares of the biopharmaceutical company’s stock after selling 1,485 shares during the quarter. Altus Wealth Group LLC’s holdings in Pfizer were worth $258,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Olistico Wealth LLC bought a new position in shares of Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC acquired a new stake in shares of Pfizer in the second quarter valued at approximately $29,000. Creekmur Asset Management LLC acquired a new position in Pfizer during the 4th quarter worth $32,000. Trivant Custom Portfolio Group LLC boosted its stake in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. bought a new stake in Pfizer during the second quarter worth about $34,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 0.4 %

Shares of PFE stock opened at $28.51 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The company has a market capitalization of $161.55 billion, a price-to-earnings ratio of -475.09, a PEG ratio of 1.02 and a beta of 0.68. The company has a 50-day simple moving average of $29.05 and a two-hundred day simple moving average of $28.04. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $35.28.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.67 EPS. Research analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were issued a $0.42 dividend. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.89%. Pfizer’s payout ratio is currently -2,799.53%.

Wall Street Analyst Weigh In

Several research firms have recently commented on PFE. UBS Group increased their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.